Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 13/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13376109 | 0.82 | ERN1 (0.41) | ERN1RXRARXRB | |
| SCHEMBL15675466 | 0.82 | APP (0.42) | ERN1SMN1; SMN2 | |
| SCHEMBL15697798 | 0.81 | ERN1 (0.55) | ERN1 | |
| SCHEMBL28311710 | 0.80 | ERN1 (0.47) | ERN1KDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL29785434 | 0.80 | ERN1 (0.47) | ERN1KDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL15674969 | 0.78 | AKR1C2 (0.41) | ERN1 | |
| SCHEMBL15675058 | 0.78 | ERN1 (0.45) | ERN1 | |
| SCHEMBL15675073 | 0.77 | TRPV1 (0.40) | ERN1 | |
| SCHEMBL15674940 | 0.77 | ERN1 (0.55) | ERN1MEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL4136634 | 0.76 | ERN1 (0.46) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207365-B2 | Polymeric salen compounds and methods thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090030172-A1 | POLYMERIC SALEN COMPOUNDS AND METHODS THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-01-29 | — | — | US | disclosed |
| WO-2006099162-A2 | POLYMERIC SALEN COMPOUNDS AND METHODS THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030172-A1 | POLYMERIC SALEN COMPOUNDS AND METHODS THEREOF | F12, CHRM1, H1-0 | ERN1 2522/4885KDM4E 3909/4885MEN1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.